Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease
- 1 April 2001
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 41 (4) , 378-385
- https://doi.org/10.1177/00912700122010230
Abstract
Fibroblast growth factor‐2 (FGF‐2) is a heparin‐binding protein capable of inducing angiogenesis in multiple animal models of chronic ischemia. The pharmacokinetics and pharmacodynamics of a single d...Keywords
This publication has 18 references indexed in Scilit:
- Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass SurgeryCirculation, 1999
- Angiogenesis Gene TherapyCirculation, 1999
- Gene Therapy for Myocardial AngiogenesisCirculation, 1998
- Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth FactorsCirculation, 1998
- Heparin Structure and Interactions with Basic Fibroblast Growth FactorScience, 1996
- Hypotensive Activity of Fibroblast Growth FactorScience, 1991
- Expression and Control of Vascular Endothelial Cells: Proliferation and Differentiation by Fibroblast Growth FactorsJournal of Investigative Dermatology, 1989
- Expression and Control of Vascular Endothelial Cells: Proliferation and Differentiation by Fibroblast Growth Factors.Journal of Investigative Dermatology, 1989
- THE HEPARIN-BINDING (FIBROBLAST) GROWTH FACTOR FAMILY OF PROTEINSAnnual Review of Biochemistry, 1989
- The Fate of Intravenously Administered bFGF and the Effect of HeparinGrowth Factors, 1989